Pharmaceutical composition for treating senile dementia

Abstract

The pharmaceutical composition for treating senile dementia relates to a medicinal product using plants as raw materials. It is an oral preparation made of medicinal active parts and conventional pharmaceutical excipients according to the conventional traditional Chinese medicine preparation process. The medicinal active parts are mainly prepared from Danshen and Panax notoginseng. Contains tanshinone II A 1.79~9.01mg, salvianolic acid B 35.87~225.23mg, danshensu 4.93~45.05mg, protocatechualdehyde 0.10~4.50mg, notoginseng saponin R13.14~22.50mg; tanshinone IIA: salvianolic acid B: The weight ratio of danshensu: protocatechualdehyde: notoginseng saponin R1 is 4-20:80-500:11-100:0.2-10:7-50. The medicament provided by the invention is effective in preventing and treating senile dementia; the active ingredient composition, content and ratio of the product are clear; the product quality is controllable and operable; and it can be mass-produced.

Description

technical field [0001] The invention relates to a medicinal product using plants as raw materials, in particular to a medicine for preparing and treating senile dementia. Background technique [0002] Alzheimer's disease is a manifestation of brain dysfunction in the early and old age. It is a disease characterized by mental decline and behavioral personality changes, including Alzheimer's disease (abbreviated as AD), vascular dementia (abbreviated as VD) ), mixed dementia and others such as trauma and Parkinson's dementia, among which Alzheimer's disease and vascular dementia are the two main types of senile dementia, and the prevalence rate accounts for more than 90% of all dementias. [0003] The pathological changes of AD are mainly characterized by senile plaques (SP) and neurofibrillary tangles (NFT). The former is mainly related to the aggregation, fibrosis and deposition of β-amyloid protein (A β). The core component of senile plaques is β-amyloid peptide (β-AP), wh...

AI Technical Summary

Problems solved by technology

[0004] The existing Western medicines for the treatment of senile dementia are mainly drugs for improving cholinergic neurotransmission, such as tacrine, Donepezil, galantamine, huperzine A, etc. Treatment modality produces inconsistent efficacy, making its use controversial

In addition, pro-metabolism drugs, hormone therapy, anti-inflammatory therapy, antioxidants, anti-amyloid, calcium channel blockers, anti-cerebral ischemia, etc. are all exploratoryly used in the treatment of AD and VD, and the curative effect remains to be confirmed.

[0005] Chinese patent CN1546112A discloses that Compound Danshen Tablets can be used to treat senile dementia, and the current clinical use is mainly to treat angina pectoris of coronary heart disease, and its process and quality standards are all formulated for the treatment of cardiovascular system diseases. The technological conditions determine that the contents of tanshinone IIA, salvianolic acid B, danshensu and protocatechualdehyde in the active ingredients of the drug are relatively low, resulting in unsatisfactory curative effect on the treatment of senile dementia; CN1348815A patent also mentions a Compound Danshen dripping pills can be used to treat senile dementia, but there are no fat-soluble components such as tanshinone IIA, protocatechualdehyde and salvianolic acid B in the active ingredients extracted by the preparation process of compound Danshen dripping pills mentioned in the patent. The content is very small, mainly containing danshensu, so it is not effective for the treatment of Alzheimer's disease, but only for the treatment of coronary heart disease and angina pectoris.

However, its content is low when it is used as medicine to treat senile dementia; compound Danshen dripping pills have no tanshinone IIA component, and the content of salvianolic acid B is low

Images